About Kleo Pharmaceuticals
Kleo Pharmaceuticals is a Healthcare company based in New Haven (United States) founded in 2015, and was acquired by Biohaven Pharmaceutical in January 2021. Developing a new class of immunotherapies utilizing small molecules to activate an individuals own immune system to fight against cancers and infectious diseases. Kleo Pharmaceuticals has raised $34.74 million across 4 funding rounds from investors including Biohaven Pharmaceutical, Gates Foundation and PeptiDream. The company has 20 employees. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is KLEO PHARMACEUTICALS INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Kleo Pharmaceuticals is developing a new class of immunotherapies utilizing small molecules to activate an individuals own immune system to fight against cancers and infectious diseases. It is developing two types of small molecules Antibody-Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). ARMs are bifunctional or two-headed chemical structures designed such that one head interacts with disease-relevant molecular targets (such as cancers), while the other head interacts directly with antibodies already present in a persons bloodstream. SyAMs are novel synthetic molecules that possess both the targeting and effector cell-activating functions of antibodies.
- Headquarters New Haven, United States
- Employees 20
- Stage Acquired
- SectorsHealthcare
- Website kleopharmaceuticals.com
- Social LinkedIn
- Acquired by Biohaven Pharmaceutical (Jan 2021)
- Legal Name Kleo Pharmaceuticals Inc
- Total Equity Funding$34.74M (USD)
in 4 rounds
- Latest Funding Round$5M (USD), Grant
Jul 2020
- InvestorsBiohaven Pharmaceutical
& 2 more
- Employee Count20
- Acquired byBiohaven Pharmaceutical
(Jan 2021)
Funding Insights of Kleo Pharmaceuticals
Kleo Pharmaceuticals has successfully raised a total of $34.74M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $5 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $34.74M
- Total Rounds 4
- Last Round Grant — $5M
- Investors Count 3
All 4 funding rounds of Kleo Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $5M | Grant | – | – | |
| Nov 2018 | $21.21M | Series B | – | PeptiDream | |
| May 2018 | $13.53M | Series A | – | – | – |
| Sep 2016 | Series A | – | Biohaven Pharmaceutical | – |
3 investors in total: 3 institutional.
Investors in Kleo Pharmaceuticals
Kleo Pharmaceuticals has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Biohaven Pharmaceutical, Gates Foundation and PeptiDream.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapies for neurological and neuropsychiatric diseases are developed. | 2014 | biohavenpharma.com | New Haven, United States | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Peptide-based drugs are developed for diverse medical indications. | 2006 | peptidream.com | Erimo, Japan |
Investor details for Kleo Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Kleo Pharmaceuticals
4 dated milestones of Kleo Pharmaceuticals across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Kleo Pharmaceuticals is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $5.0M.
- Exit Acquired by Biohaven Pharmaceutical.
Competitors of Kleo Pharmaceuticals
Kleo Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Kleo Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Kleo Pharmaceuticals (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kleo Pharmaceuticals
Complete news archive for Kleo Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kleo Pharmaceuticals
Kleo Pharmaceuticals was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Kleo Pharmaceuticals is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Kleo Pharmaceuticals is a funded company, having raised a total of $34.74M across 4 funding rounds to date.
Kleo Pharmaceuticals has 20 employees.
Kleo Pharmaceuticals is developing a new class of immunotherapies utilizing small molecules to activate an individuals own immune system to fight against cancers and infectious diseases. It is developing two types of small molecules Antibody-Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). ARMs are bifunctional or two-headed chemical structures designed such that one head interacts with disease-relevant molecular targets (such as cancers), while the other head interacts directly with antibodies already present in a persons bloodstream. SyAMs are novel synthetic molecules that possess both the targeting and effector cell-activating functions of antibodies.
Kleo Pharmaceuticals has 3 investors. Key investors include Biohaven Pharmaceutical, Gates Foundation, and PeptiDream.
Kleo Pharmaceuticals operates through Kleo Pharmaceuticals Inc.
Yes. Kleo Pharmaceuticals was acquired by Biohaven Pharmaceutical in January 2021.